Status:
COMPLETED
A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)
Lead Sponsor:
Qian Chu
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-s...
Detailed Description
A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-s...
Eligibility Criteria
Inclusion
- Age: ≥18 years old, no gender limit.
- Diagnosed as advanced non-small cell lung cancer.
- At least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm.
- Doctors evaluate the benefits of receiving Anlotinib treatment.
- The patient voluntarily joins the project and signs the informed consent. If any of the above items is "No", the patient is not suitable for this study.
Exclusion
- Those who have been confirmed to be allergic to anlotinib and/or its excipients.
- Patients with anlotinib contraindications.
Key Trial Info
Start Date :
July 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 16 2022
Estimated Enrollment :
373 Patients enrolled
Trial Details
Trial ID
NCT04871997
Start Date
July 12 2019
End Date
July 16 2022
Last Update
October 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hubei province
Wuhan, Hubei, China, 430030